Biologically Active Small Molecules

A sulfide-like inhibitor of PDE7 (IC₅₀ = 2.1 &microM).

An inhibitor of S1P lyase treatment of mice (50 &microg/ml in drinking water) increases lymphoid tissue S1P concentrations 100-fold, reducing lymphocyte egress from thymus and peripheral lymphoid organs, resulting in reversible lymphopenia.

An inhibitor of S1P lyase treatment of mice (50 &microg/ml in drinking water) increases lymphoid tissue S1P concentrations 100-fold, reducing lymphocyte egress from thymus and peripheral lymphoid organs, resulting in reversible lymphopenia.

An inhibitor of S1P lyase treatment of mice (50 &microg/ml in drinking water) increases lymphoid tissue S1P concentrations 100-fold, reducing lymphocyte egress from thymus and peripheral lymphoid organs, resulting in reversible lymphopenia.

An inhibitor of S1P lyase treatment of mice (50 &microg/ml in drinking water) increases lymphoid tissue S1P concentrations 100-fold, reducing lymphocyte egress from thymus and peripheral lymphoid organs, resulting in reversible lymphopenia.

A selective, cell-active inhibitor of NOX1 that blocks the generation of ROS in HT-29 cells (IC₅₀ = 0.129 &microM) abolishes collagen-induced superoxide production by platelets (IC₅₀ = 306 nM).

A selective, cell-active inhibitor of NOX1 that blocks the generation of ROS in HT-29 cells (IC₅₀ = 0.129 &microM) abolishes collagen-induced superoxide production by platelets (IC₅₀ = 306 nM).

A selective, cell-active inhibitor of NOX1 that blocks the generation of ROS in HT-29 cells (IC₅₀ = 0.129 &microM) abolishes collagen-induced superoxide production by platelets (IC₅₀ = 306 nM).

A selective, cell-active inhibitor of NOX1 that blocks the generation of ROS in HT-29 cells (IC₅₀ = 0.129 &microM) abolishes collagen-induced superoxide production by platelets (IC₅₀ = 306 nM).

A synthetic intermediate useful for pharmaceutical synthesis.

A synthetic intermediate useful for pharmaceutical synthesis.

A synthetic intermediate useful for pharmaceutical synthesis.